| SARS-CoV-2 B. 1.617. 2 Delta variant replication and immune evasion P Mlcochova, SA Kemp, MS Dhar, G Papa, B Meng, IATM Ferreira, R Datir, ... Nature 599 (7883), 114-119, 2021 | 1336 | 2021 |
| Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity B Meng, A Abdullahi, IATM Ferreira, N Goonawardane, A Saito, I Kimura, ... Nature 603 (7902), 706-714, 2022 | 966 | 2022 |
| Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant R Suzuki, D Yamasoba, I Kimura, L Wang, M Kishimoto, J Ito, Y Morioka, ... Nature 603 (7902), 700-705, 2022 | 626 | 2022 |
| Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation A Saito, T Irie, R Suzuki, T Maemura, H Nasser, K Uriu, Y Kosugi, ... Nature 602 (7896), 300-306, 2022 | 558 | 2022 |
| SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity C Motozono, M Toyoda, J Zahradnik, A Saito, H Nasser, TS Tan, I Ngare, ... Cell host & microbe 29 (7), 1124-1136. e11, 2021 | 538 | 2021 |
| SARS-CoV-2 ORF3b is a potent interferon antagonist whose activity is increased by a naturally occurring elongation variant Y Konno, I Kimura, K Uriu, M Fukushi, T Irie, Y Koyanagi, D Sauter, ... Cell reports 32 (12), 2020 | 493 | 2020 |
| Virological characteristics of the SARS-CoV-2 Omicron BA. 2 spike D Yamasoba, I Kimura, H Nasser, Y Morioka, N Nao, J Ito, K Uriu, ... Cell 185 (12), 2103-2115. e19, 2022 | 297 | 2022 |
| Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants T Tamura, J Ito, K Uriu, J Zahradnik, I Kida, Y Anraku, H Nasser, M Shofa, ... Nature communications 14 (1), 2800, 2023 | 269 | 2023 |
| Virological characteristics of the SARS-CoV-2 Omicron BA. 2 subvariants, including BA. 4 and BA. 5 I Kimura, D Yamasoba, T Tamura, N Nao, T Suzuki, Y Oda, S Mitoma, J Ito, ... Cell 185 (21), 3992-4007. e16, 2022 | 254 | 2022 |
| Neutralization of the SARS-CoV-2 Mu variant by convalescent and vaccine serum K Uriu, I Kimura, K Shirakawa, A Takaori-Kondo, T Nakada, A Kaneda, ... New England Journal of Medicine 385 (25), 2397-2399, 2021 | 220 | 2021 |
| Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies D Yamasoba, Y Kosugi, I Kimura, S Fujita, K Uriu, J Ito, K Sato The Lancet Infectious Diseases 22 (7), 942-943, 2022 | 217 | 2022 |
| The SARS-CoV-2 Lambda variant exhibits enhanced infectivity and immune resistance I Kimura, Y Kosugi, J Wu, J Zahradnik, D Yamasoba, EP Butlertanaka, ... Cell reports 38 (2), 2022 | 206 | 2022 |
| Virological characteristics of the SARS-CoV-2 JN. 1 variant Y Kaku, K Okumura, M Padilla-Blanco, Y Kosugi, K Uriu, AA Hinay, ... The Lancet Infectious Diseases 24 (2), e82, 2024 | 198 | 2024 |
| Cell-to-cell infection by HIV contributes over half of virus infection S Iwami, JS Takeuchi, S Nakaoka, F Mammano, F Clavel, H Inaba, ... Elife 4, e08150, 2015 | 173 | 2015 |
| IFITM proteins promote SARS-CoV-2 infection and are targets for virus inhibition in vitro C Prelli Bozzo, R Nchioua, M Volcic, L Koepke, J Krüger, D Schütz, ... Nature communications 12 (1), 4584, 2021 | 169 | 2021 |
| SARS-CoV-2 B. 1.617 mutations L452R and E484Q are not synergistic for antibody evasion IATM Ferreira, SA Kemp, R Datir, A Saito, B Meng, P Rakshit, ... The Journal of infectious diseases 224 (6), 989-994, 2021 | 160 | 2021 |
| SARS-CoV-2 B. 1.617. 2 Delta variant replication, sensitivity to neutralising antibodies and vaccine breakthrough P Mlcochova, S Kemp, MS Dhar, G Papa, B Meng, S Mishra, C Whittaker, ... | 145* | 2021 |
| Modulation of human immunodeficiency virus type 1 infectivity through incorporation of tetraspanin proteins K Sato, J Aoki, N Misawa, E Daikoku, K Sano, Y Tanaka, Y Koyanagi Journal of Virology 82 (2), 1021-1033, 2008 | 143 | 2008 |
| Virological characteristics of the SARS-CoV-2 Omicron BA. 2.75 variant A Saito, T Tamura, J Zahradnik, S Deguchi, K Tabata, Y Anraku, I Kimura, ... Cell host & microbe 30 (11), 1540-1555. e15, 2022 | 138 | 2022 |
| Virological characteristics of the SARS-CoV-2 omicron XBB. 1.16 variant D Yamasoba, K Uriu, A Plianchaisuk, Y Kosugi, L Pan, J Zahradnik, J Ito, ... The Lancet Infectious Diseases 23 (6), 655-656, 2023 | 124 | 2023 |
